Artificial intelligence-based tumor size measurement on mammography: agreement with pathology and comparison with human readers' assessments across multiple imaging modalities.

Purpose: To evaluate the agreement between artificial intelligence (AI)-based tumor size measurements of breast cancer and the final pathology and compare these results with those of other imaging modalities.

Material And Methods: This retrospective study included 925 women (mean age, 55.3 years ± 11.6) with 936 breast cancers, who underwent digital mammography, breast ultrasound, and magnetic resonance imaging before breast cancer surgery. AI-based tumor size measurement was performed on post-processed mammographic images, outlining areas with AI abnormality scores of 10, 50, and 90%. Absolute agreement between AI-based tumor sizes, image modalities, and histopathology was assessed using intraclass correlation coefficient (ICC) analysis. Concordant and discordant cases between AI measurements and histopathologic examinations were compared.

Results: Tumor size with an abnormality score of 50% showed the highest agreement with histopathologic examination (ICC = 0.54, 95% confidential interval [CI]: 0.49-0.59), showing comparable agreement with mammography (ICC = 0.54, 95% CI: 0.48-0.60, p = 0.40). For ductal carcinoma in situ and human epidermal growth factor receptor 2-positive cancers, AI revealed a higher agreement than that of mammography (ICC = 0.76, 95% CI: 0.67-0.84 and ICC = 0.73, 95% CI: 0.52-0.85). Overall, 52.0% (487/936) of cases were discordant, with these cases more commonly observed in younger patients with dense breasts, multifocal malignancies, lower abnormality scores, and different imaging characteristics.

Conclusion: AI-based tumor size measurements with abnormality scores of 50% showed moderate agreement with histopathology but demonstrated size discordance in more than half of the cases. While comparable to mammography, its limitations emphasize the need for further refinement and research.